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Summary Cytokeratin 19 fragment (CYFRA 21-1) level in serum have already been
documented as a useful tumor marker for lung cancer. In the present study, we
hypothesized that CYFRA 21-1 increases in the sera of patients with radiation
pneumonitis, resulting from epithelial cell damage. We measured CYFRA 21-1 in the
sera of patients with radiation pneumonitis and evaluated the correlation between
CYFRA 21-1 level and severity of radiation pneumonitis as well as clinical course. We
studied 16 patients diagnosed with radiation pneumonitis associated with primary
lung cancer. CYFRA 21-1 levels in the sera of patients with diffuse radiation
pneumonitis (n ¼ 6) significantly increased compared to normal smokers (n ¼ 10) or
patients with local radiation pneumonitis (n ¼ 10). CYFRA 21-1 values in sera
changed according to the progression or improvement of the diffuse radiation
pneumonitis. An immunohistochemical study using pulmonary tissues obtained from
autopsied patients with radiation pneumonitis demonstrated that the hyaline
membrane and proliferating type II pneumocytes were strongly stained by the anti-
human cytokeratin 19 antibody. Our data demonstrated that CYFRA 21-1 was
increased in patients with diffuse radiation pneumonitis. Since CYFRA 21-1 is widely
used as a tumor marker for lung cancer, this evidence should be noted especially in
irradiated patients.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
There are approximately 40 different cell types in
the lung.1 Among them, the type II pneumocytes
are the principal source of surfactant and have the
fastest turnover rate. Since radiation injury is
secondary to mitotic cell death, the type II
pneumocyte is most closely linked to the mechan-
istic theories underlying radiation pneumonitis.2
Pathophysiologically, it has been reported that
radiation pneumonitis is an alveolitis resulting from
damage to the alveolar type II pneumocytes that
maintain alveolar patency.2
Cytokeratin is a cytoskeletal structure expressed
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cytokeratin are known. Of these cytokeratins,
cytokeratin 19 is especially expressed in simple
epithelia, including bronchial epithelial cells.3–6
Although the precise mechanisms of their genera-
tion are unknown, cytokeratin 19 fragment(CYFRA
21-1) is soluble in serum and can be detected with
the aid of monoclonal antibodies in patients with
lung cancer.7–10 However, there have been no
studies evaluating the clinical significance of CYFRA
21-1 in sera of patients with radiation pneumonitis.
Since it has been suggested that CYFRA 21-1 is
released from injured bronchial epithelium,11 we
hypothesized that the levels of CYFRA 21-1 in sera
also increase in patients with radiation pneumoni-
tis, and CYFRA 21-1 values in sera correlate with
the clinical course. Under this background, we




In Kagawa Medical University Hospital (613 beds),
we studied 16 patients with a diagnosis of radiation
pneumonitis (1 female and 15 males; 2 ex-smokers
and 14 current smokers). Their median age was 71
years with a range of 53–85 years.
The diagnoses of radiation pneumonitis were
made by clinical, radiological, and physiological
grounds. The criteria for diffuse radiation pneumo-
nitis were defined as follows; (i) an interstitial
shadow extending outside of irradiation field, (ii) a
fall in arterial oxygen partial pressure of less than
60mmHg in room air, (iii) absence of infectious
pneumonia, and (iv) the need to administer steroid
hormones to improve respiratory failure. Pneumo-
nitis grading was defined using the National Cancer
Institute Common Toxicity Criteria. NCI pneumoni-
tis grading system defines Grade 1 as radiographic
changes but asymptomatic or symptoms not requir-
ing steroids. NCI Grade 2 pneumonitis is defined as
radiographic changes and requiring steroids or
diuretics. NCI Grade 3 pneumonitis is defined as
radiographic changes and requiring oxygen. Grade 4
pneumonitis is for those with radiographic changes
and requiring assisted ventilation. The localized
radiation pneumonitis was defined as interstitial
shadow within the irradiated field. In all patients,
high-resolution computed radiographic scanning of
the lungs (HRCT) was performed. Among 16
patients, 6 patients were classified to have diffuse
radiation pneumonitis (grade 3 or 4) and 10
patients were classified to have focal radiation
pneumonitis (all grade 1). Characteristics of 6
patients with diffuse radiation pneumonitis are
listed in Table 1. CYFRA 21-1 were successively
measured in 5 patients with diffuse radiation
pneumonitis.
We also studied 10 normal smokers (smoking at
least a pack/day, 9 men and 1 woman) who had an
average age of 55 years. All subjects had no history
of lung diseases or clinical findings suggesting lung
disease, and all subjects had normal liver and renal
function. They all had normal chest X-rays and their
pulmonary function test results were within a
normal range.
The ethics committees of the Kagawa Medical
University approved the study, and all patients
provided written informed consent before enroll-
ment. The study was performed in accordance with
the latest revisions to the Declaration of the
Helsinki.
Blood samples
Peripheral venous blood samples with and without
ethylenediaminetetraacetic acid (EDTA) were ob-
tained before breakfast. After centrifugation at
1000g for 10min at 41C, the serum was frozen and
stored at 701C until used. Arterial blood samples
were analysed for PaO2 and PaCO2 using a blood gas
analyzer.
Measurement of CYFRA 21-1 levels in serum
and correlation with clinical courses
CYFRA 21-1 in serum was measured with a two-step
sandwich immunoassay using the streptavidin-bio-
tin technique (Enzymun-Test CYFRA21-1; Boehrin-
ger Mannheim GmbH, Tutzing, Germany). The
lower detection limit of this assay was 0.1 ng/ml.
Data are expressed as mean values from duplicate
determinations.
In patients with radiation pneumonitis, the
correlation between CYFRA 21-1 and the clinical
course was evaluated.
Pathological and immunohistochemical
examination of the autopsied lung
To evaluate the expression of cytokeratin 19 in lung
tissues obtained by autopsy. Paraffin embedded and
dewaxed lung sections were immunohistochemi-
cally stained, employing the avidin-biotin perox-
idase complex method (Dako LSAB kit-peroxidase,
DAKO Corp., Kyoto, Japan) using mouse monoclonal
antibody to cytokeratin 19; in 1:30 dilution,
commercially purchased from ScyTek Laboratories
(Logan, UT, USA). In order to enhance the immune
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Table 1 Patient characteristics.
Case Age and
sex






1 67 Male Small cell lung cancer 4 CBDCAþADMþVP-16 50.4 (1.2Gy 2/day) 10 8 PR
2 74 Male Adenocarcinoma 4 None 60 (2Gy 1/day) 12 10 PR
3 71 Male Small cell lung cancer 3 CBDCAþADMþVP-16 55.2 (1.2Gy 2/day) 12 11 PR
4 53 Male Adenocarcinoma 4 CBDCAþTaxotere 55.2 (1.2Gy 2/day) 10 10 PR
5 62 Male Squamous cell carcinoma 4 CBDCAþTaxotere 50 (2Gy 1/day) 9 6 PR




Pattern CYFRA (ng/ml) Therapy Prognosis
Initial Before After After therapy
11 Diffuse NEn 2.5 36.6 NE Steroid Deadw
2 Diffuse NE NE 45 NE Steroid Deadw
2 Diffuse 1 0.9 9.5 0.9 SteroidþCyclosporin A Improved
5 Diffuse 21.3 3.7 37.7 NE Steroid Dead
3 Diffuse 12.3 5 50 NE Steroid þCyclosporin A Deadw











reaction, dewaxed sections were pretreated with
autoclave at 1321C for 12min in 10mM citrate
buffer (pH 6.0). Staining procedures were accord-
ing to the kit manual.
Histopathological findings of the lung of three
autopsied cases were as follows. In case 1, each
lobe of the lung was found to have organizing
diffuse alveolar damage (DAD). The collapse of
alveoli with fibrosis was more severe in the
subpleural region, than in the deeper part, and
irregular small multicystic changes associated with
organized hyaline membranes were widely found.
Proliferating type II alveolar cells with atypism
were found in the intervening areas of small cystic
change. In case 1, organizing DAD (acute interstitial
pneumonia) was found in both lungs. A few
remaining cancer cells were detected in the right
lower lobe. The findings of case 2 and case 5,
generally resembled case 1. Only a few remaining
cancer cells were detected. All three autopsied
cases were diagnosed to be bilateral radiation
pneumonitis with a DAD pattern.
Statistical methods
Results are expressed as mean values7standard
error of the mean. Comparisons of values between
the two groups were analysed with the Mann–
Whitney U-test. A P-value less than 0.05 was
considered to be statistically significant.
Results
CYFRA 21-1 levels in sera of patients with focal
radiation pneumonitis (1.7470.28 ng/ml,
mean7standard error) was significantly elevated
as compared with normal smokers (1.070.13 ng/
ml) (Po0:02) as shown in Fig. 1. In addition, CYFRA
21-1 levels in sera of patients with diffuse radiation
pneumonitis (30.977.5 ng/ml, mean7standard er-
ror) were significantly elevated as compared with
local radiation pneumonitis (1.7470.28) and nor-
mal smokers (1.070.13 ng/ml) (Po0:002 in both
comparisons). Serum CYFRA 21-1 levels in patients
with radiation pneumonitis were changed according
to the treatment as shown in Fig. 2A and B. Patients
were treated with the pulse therapy of intravenous
methylprednisolone (1 g/day for 3 days) and fol-
lowed by oral prednisolone (1mg/kg). In patients
with deteriorated radiation pneumonitis (case 1, 4
and 5), CYFRA 21-1 levels increased according to
the clinical course (Fig. 2A. In addition, in a case
(case 3) in whom radiation pneumonitis was
improved by treatment, CYFRA 21-1 values de-
creased according to the clinical course (Fig. 2B).
Interestingly, CYFRA 21-1 levels in serum did not
correlate with CRP values in sera (Fig. 3).
Immunostaining of the hyaline membrane with
anti-human cytokeratin 19 monoclonal antibody
was positive in an autopsy case of radiation
pneumonitis as shown in Fig. 4A, featuring some-
what lamellar structure. Detached epithelial cells
were also stained (Fig. 4A). Proliferating type II
pneumocytes lining irregular alveolar spaces were
stained much more densely than the hyaline
membrane, as revealed in Fig. 4B. Cytoplasm of
CD68 positive intraalveolar macrophages was also
weakly stained (Fig. 4C).
Discussion
In the present study, it was demonstrate that the
CYFRA 21-1 levels in sera of patients with diffuse
radiation pneumonitis were significantly higher as
compared with local radiation pneumonitis or
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Figure 1 Serum cytokeratin 19 fragment levels (ng/ml)
in normal smokers, patients with local radiation pneu-
monitis, and diffuse radiation pneumonitis. Bar repre-
sents meanþ standard deviation. *Po0:002; **Po0:02:
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normal smokers, and CYFRA 21-1 levels in sera were
significantly correlated with the clinical course in
patients with radiation pneumonitis. In addition,
CYFRA 21-1 values in sera of patients with
deteriorating radiation pneumonitis were extraor-
dinarily high. Furthermore, immunohistochemical
staining demonstrated that cytokeratin 19 was
stained in moderate density at the site of the
hyaline membrane. This evidence suggests that
CYFRA 21-1 levels in serum reflected the disease
activity in patients with radiation pneumonitis, and
CYFRA 21-1 was a useful marker to prove the
existence of epithelial cell damage.
The accepted explanation for development of
radiation pneumonitis has largely centered around
the process of cellular damage, particularly the
type II pneumocytes, and the resultant alteration in
production and release of pulmonary surfactant
that is needed to prevent atelectasis of the lung.12
In radiation induced lung injury, it has been
suggested that apoptosis of type II pneumocytes
plays an important role.13 Recently, a review article
about lung toxicity following chest irradiation in
patients with lung cancer14 and several original
articles concerning the pathogenesis of radiation-
induced lung injury have been published.15–18
It has been suggested that CYFRA 21-1 is a marker
of apoptosis in several human cancers.19–21 There-
fore, following cell injury caused by radiation,
fragments of cytokeratin 19 might be released from
type II pneumocytes during the process of radia-
tion-induced epithelial cell damage. In addition, a
part of cytokeratin 19 derived from damaged or
apoptotic type II pneumocytes might be a compo-
nent of hyaline membrane.
As demonstrated in the present study, successive
measurement of serum CYFRA 21-1 and CRP
resulted in the increased value of serum CYFRA
21-1, but not CRP. CRP is produced from hepatocyte
by the stimulation of interleukin-1, interleukin-6,
and TNF-a: These cytokines were suppressed by
corticosteroids, and then CRP decreased immedi-
ately after the steroid treatment. In contrast,
epithelial cell damage as well as successive repair
by alveolar type II cells may have reflected the
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Figure 2 Changes of serum cytokeratin 19 fragment levels (ng/ml) according to clinical courses in 5 patients with
diffuse radiation pneumonitis. (A) Deteriorated cases; (B) an improved case. In patients with radiation pneumonitis,
CYFRA 21-1 levels increased according to the progressing clinical course (A). In contrast, a case in which radiation
pneumonitis had improved by treatment, CYFRA 21-1 levels decreased according to the improving clinical course (B).
Figure 3 Changes of serum CYFRA 21-1 levels (ng/ml,
J) and CRP values (mg/dl, K) along with the clinical
course of a patient with diffuse radiation pneumonitis.
The arrow represents the onset of radiation pneumonitis.
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increase of CYFRA 21-1. Therefore, there may have
been a discrepancy between the CRP values and
CYFRA 21-1 values.
Since CYFRA 21-1 levels in sera frequently
increase in patients with lung cancer, elevation of
CYFRA 21-1 might be caused by the progression of
lung cancer itself (for example, lymphangitis
carcinomatosa). However, in the present study,
lung cancer was well controlled in most patients
clinically, the possibility of the progression of lung
cancer was very low. In addition, in 3 autopsied
cases, lung cancer was well controlled and the mass
of remnant tumor was too small to explain values of
serum CYFRA 21-1. Therefore, the possibility of
lymphangitis carcinomatosa was not considered by
either clinical findings or autopsy findings.
Although there are some limitations for measur-
ing CYFRA 21-1 in lung cancer patients, it should be
stressed that levels of CYFRA 21-1 in sera could
increase in patients with radiation pneumonitis. In
addition, since CYFRA 21-1 was only released from
injured epithelial cells, levels of CYFRA 21-1
directly reflected the degree of epithelial cell
damage as demonstrated in immunohistochemistry.
Since the present study is retrospective, a
prospective study evaluating the usefulness of
CYFRA 21-1 measurement in patients who receive
radiation therapy should be performed.
In conclusion, our data demonstrate (i) CYFRA
21-1 in serum increased in patients with diffuse
radiation pneumonitis, and (ii) CYFRA 21-1 in serum
correlated with the clinical course in radiation
pneumonitis. These results suggest that the eleva-
tion of CYFRA 21-1 seemed to be a marker of lung
epithelial cell damage, possibly caused by apopto-
sis of epithelial cells from radiation pneumonitis.
Physicians should also consider that the elevation of
CYFRA 21-1 was also caused by radiation pneumo-
nitis instead of recurrence of primary lung cancer.
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